Share This Page
EUTHYROX Drug Patent Profile
✉ Email this page to a colleague
When do Euthyrox patents expire, and when can generic versions of Euthyrox launch?
Euthyrox is a drug marketed by Emd Serono Inc and is included in one NDA.
The generic ingredient in EUTHYROX is levothyroxine sodium. There is one drug master file entry for this compound. Fifty suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Euthyrox
A generic version of EUTHYROX was approved as levothyroxine sodium by MYLAN on June 5th, 2002.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for EUTHYROX?
- What are the global sales for EUTHYROX?
- What is Average Wholesale Price for EUTHYROX?
Summary for EUTHYROX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 77 |
| Clinical Trials: | 9 |
| Drug Prices: | Drug price information for EUTHYROX |
| What excipients (inactive ingredients) are in EUTHYROX? | EUTHYROX excipients list |
| DailyMed Link: | EUTHYROX at DailyMed |
Recent Clinical Trials for EUTHYROX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Peking Union Medical College Hospital | NA |
| Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Phase 1 |
| First People's Hospital of Hangzhou | Phase 4 |
US Patents and Regulatory Information for EUTHYROX
Euthyrox Market Dynamics and Financial Trajectory
Euthyrox is a mature levothyroxine sodium brand marketed by Merck KGaA for thyroid hormone replacement. Its market is defined by durable medical demand, high generic substitution, low unit-price growth, and limited product-level disclosure. Merck does not report Euthyrox revenue separately, so its financial trajectory cannot be isolated from public filings. The brand remains commercially relevant in markets where physicians and patients prefer branded levothyroxine, but it lacks the exclusivity profile of a growth pharmaceutical product.
What is Euthyrox and who markets it?
Euthyrox contains levothyroxine sodium, a synthetic form of thyroxine used to treat hypothyroidism and suppress thyroid-stimulating hormone in selected thyroid disorders. Merck KGaA, headquartered in Darmstadt, Germany, is the principal global manufacturer and marketer.
The U.S. product is marketed under NDA 021301. FDA labeling identifies the product as a levothyroxine sodium tablet and lists the initial U.S. approval in 2000 (U.S. Food and Drug Administration [FDA], 2023).
Euthyrox is sold in multiple strengths, generally ranging from 25 micrograms to 300 micrograms. The brand is distributed across Europe, Latin America, Asia, the Middle East and other international markets. Market ownership and commercial rights can differ by country because levothyroxine brands are subject to local registrations, tender systems, distributors and licensing arrangements.
Euthyrox product profile
| Attribute | Euthyrox position |
|---|---|
| Active ingredient | Levothyroxine sodium |
| Therapeutic area | Endocrinology |
| Primary use | Hypothyroidism and thyroid hormone replacement |
| Dosage form | Oral tablet |
| U.S. regulatory application | NDA 021301 |
| U.S. approval status | Approved prescription product |
| Manufacturer | Merck KGaA |
| Product type | Mature small-molecule brand |
| Primary substitutes | Generic levothyroxine, Synthroid, Levoxyl, Unithroid, Tirosint |
| Exclusivity status | No current market exclusivity comparable to a new chemical entity |
How large is the Euthyrox market?
The underlying levothyroxine market is large and structurally stable because hypothyroidism usually requires long-term, often lifelong, treatment. Demand is supported by thyroid disease prevalence, routine screening, aging populations and continued diagnosis of subclinical hypothyroidism.
The commercial market is divided into:
- Low-cost generic levothyroxine tablets.
- Branded tablets such as Euthyrox, Synthroid, Levoxyl and Unithroid.
- Premium softgel and liquid formulations such as Tirosint and Tirosint-SOL.
- Country-specific brands and hospital-tender products.
Volume demand is resilient, but revenue growth is constrained. Levothyroxine is an established molecule with multiple manufacturers, interchangeable products and limited scope for premium pricing in standard tablet formulations.
In the United States, generic levothyroxine is widely dispensed. Brand demand persists when physicians or patients seek consistency of product, when insurance design favors a particular brand, or when a patient reports difficulty maintaining thyroid-stimulating hormone control after switching products.
What is the financial trajectory of Euthyrox?
Euthyrox revenue is not disclosed as a separate line item in Merck KGaA’s annual reports. The company reports financial performance by business sector and major product groups, not by every mature brand. Public filings therefore do not support a reliable product-level revenue or margin series for Euthyrox.
Merck KGaA reports Euthyrox within its Healthcare activities. The Healthcare segment is materially larger than Euthyrox and is driven by products such as Mavenclad, Rebif, Erbitux, Bavencio and other specialty medicines. Euthyrox is not identified as a principal growth driver in the company’s investor disclosures (Merck KGaA, 2023, 2024).
Financial trajectory by phase
| Period | Euthyrox commercial trajectory | Main drivers |
|---|---|---|
| Early commercialization | Expansion through country registrations and brand establishment | Growing diagnosed patient base and physician familiarity |
| Mature branded phase | Stable or declining value in competitive markets | Generic substitution and price pressure |
| Current phase | Defensive, volume-supported revenue profile | Chronic demand, local brand loyalty and international sales |
| Forward outlook | Low-single-digit or declining value absent formulation innovation | Tender erosion, generic competition and reimbursement controls |
The most defensible conclusion is that Euthyrox is a cash-generating mature brand rather than a high-growth asset. Its financial value depends on manufacturing scale, supply reliability, geographic coverage and brand retention. It is unlikely to produce substantial organic revenue growth through price increases in the standard tablet market.
How do generic competition and pricing affect Euthyrox?
Generic competition is the central market force. Levothyroxine has been available from multiple manufacturers for decades, and FDA-approved generic products are listed as therapeutically equivalent to the relevant reference products when assigned an “AB” rating in the Orange Book (FDA, 2024).
The main effects are:
- Lower average selling prices for standard tablets.
- Greater pharmacy substitution.
- Increased payer control over formulary placement.
- Periodic switching between manufacturers.
- Reduced ability to defend share through price.
- Higher commercial value for differentiated dosage forms.
Levothyroxine is a narrow-therapeutic-index product. Small changes in exposure can affect thyroid-stimulating hormone levels, particularly in sensitive patients, pregnant patients and patients with cardiac disease. The FDA has established product-specific bioequivalence requirements, but these requirements do not eliminate substitution pressure for approved generic products (FDA, 2014).
Euthyrox can retain a branded position where prescribers emphasize consistency of manufacturer or where patients remain stable on the product. That advantage is commercial, not equivalent to patent exclusivity.
What patents protect Euthyrox?
Euthyrox’s core active ingredient, levothyroxine sodium, is an old molecule. Composition-of-matter patent protection has expired. The standard Euthyrox tablet therefore does not have the type of active foundational patent estate associated with recently approved small-molecule drugs.
| Protection category | Euthyrox position |
|---|---|
| Active-ingredient patent | Expired |
| New chemical entity exclusivity | Expired |
| Core tablet formulation protection | No publicly identified current barrier that prevents generic levothyroxine tablets |
| Method-of-use patents | No broad, commercially decisive Euthyrox method-of-use barrier identified |
| Manufacturing know-how | Potentially relevant, but generally difficult to use as a broad market exclusion |
| Trademark | Commercially important and country-specific |
| Regulatory exclusivity | Not a current primary barrier to generic entry |
Patent risk is therefore low for the core tablet product. Any relevant formulation, manufacturing or process patents would need to be assessed by jurisdiction and claim scope. Such rights would not normally recreate the protection of an active-ingredient patent unless they covered a clinically important and commercially necessary formulation.
What is the Orange Book status of Euthyrox?
The U.S. Orange Book identifies approved drug products, therapeutic equivalence evaluations and listed patent or exclusivity information (FDA, 2024). Euthyrox’s commercial position is based primarily on its approved NDA and brand identity, not on unexpired composition patents or active regulatory exclusivity.
Generic levothyroxine manufacturers can pursue abbreviated new drug applications under the ANDA pathway. FDA approval and therapeutic-equivalence determinations allow substitution subject to state pharmacy law, payer policy and prescriber instructions.
The practical Orange Book implication is that Euthyrox faces ordinary generic competition. A current Orange Book review should be performed for the applicable edition when evaluating a specific ANDA or litigation position, because listings and regulatory records can change.
When does Euthyrox lose exclusivity?
Euthyrox has already lost the exclusivity associated with a newly approved chemical entity. Its U.S. approval dates to 2000, and levothyroxine products from multiple manufacturers have been available for many years.
The relevant commercial timeline is:
| Milestone | Approximate timing |
|---|---|
| Initial U.S. Euthyrox approval | 2000 |
| Generic levothyroxine competition | Established before the current commercial period |
| Current market status | Mature, multi-source product |
| Future loss of core exclusivity | Not applicable; core exclusivity has already expired |
There is no single future “patent cliff” comparable to the expected loss of exclusivity for a recently launched specialty drug. Revenue erosion occurs progressively through substitution, reimbursement pressure and local price competition.
Which companies challenge Euthyrox commercially?
Euthyrox competes against both branded and generic manufacturers.
Principal competitors
| Competitor | Company or manufacturer | Competitive position |
|---|---|---|
| Generic levothyroxine | Multiple FDA-approved manufacturers | Lowest-cost and highest substitution pressure |
| Synthroid | AbbVie | Major U.S. branded tablet competitor |
| Levoxyl | Pfizer | Branded levothyroxine tablet |
| Unithroid | Amneal Pharmaceuticals | Branded tablet competitor |
| Tirosint | IBSA | Softgel formulation with premium positioning |
| Tirosint-SOL | IBSA | Liquid formulation targeting absorption and administration needs |
| Country-specific brands | Local and multinational companies | Important in non-U.S. markets |
Tirosint and Tirosint-SOL compete differently from standard Euthyrox tablets. Their commercial proposition is based on formulation, absorption, excipient profile and administration flexibility rather than simply on levothyroxine content.
What formulations are protected against Euthyrox competition?
The standard Euthyrox tablet has limited differentiation. Formulation-based competition is more commercially significant in patients with absorption variability, excipient intolerance, gastrointestinal conditions or difficulty taking tablets.
Potentially defensible formulation attributes include:
- Softgel delivery.
- Oral liquid delivery.
- Reduced excipient load.
- Improved administration flexibility.
- Packaging designed to protect potency and stability.
- Manufacturing controls that support dose uniformity.
These attributes may support trademarks, formulation patents, regulatory exclusivity or physician preference, depending on the product and jurisdiction. They do not automatically protect Euthyrox itself. Euthyrox’s principal product remains a conventional oral tablet, leaving it exposed to generic tablet competition.
What manufacturing and intellectual-property barriers affect Euthyrox?
Levothyroxine manufacturing requires tight control of potency, content uniformity, degradation products and stability. The active ingredient is used at microgram doses, which increases the importance of blending, granulation, compression and analytical testing.
Manufacturing barriers include:
- Reliable sourcing of pharmaceutical-grade levothyroxine.
- Accurate low-dose content uniformity.
- Stability through shelf life.
- Consistent dissolution.
- Regulatory control of manufacturing changes.
- Supply continuity across multiple strengths.
These barriers can create operational advantages but do not necessarily create enforceable market exclusivity. A competitor with an approved product and validated manufacturing process can compete directly.
Supply interruptions can temporarily increase the value of a branded product. They can also trigger regulatory scrutiny, pharmacy switching and inventory substitution. For a mature thyroid medicine, execution and supply reliability may have greater commercial importance than patent ownership.
What is the Paragraph IV challenge risk for Euthyrox?
Paragraph IV risk is structurally high because the product has long been exposed to ANDA competition and its core patent protection has expired. New Paragraph IV disputes would most likely concern:
- A newly listed formulation patent.
- A specific dosage form.
- A manufacturing process.
- A stability or delivery technology.
- A brand’s attempt to list patents associated with a reformulated product.
A generic applicant may certify that a listed patent is invalid, unenforceable or will not be infringed. For conventional Euthyrox tablets, the principal competitive threat is not a future patent challenge but continued authorized and generic substitution.
What litigation and settlement agreements affect Euthyrox?
No single active U.S. litigation or settlement agreement is publicly established as the main determinant of Euthyrox’s current global market position. Litigation risk is more likely to arise at the product, manufacturer or formulation level than from a broad Euthyrox patent estate.
Potential disputes include:
- Trademark and trade-dress claims.
- ANDA patent litigation involving a reformulated levothyroxine product.
- Manufacturing and supply-contract disputes.
- Product liability claims involving dose stability or switching.
- Regulatory challenges concerning bioequivalence or manufacturing changes.
Settlement agreements would need to be analyzed individually because a settlement involving Synthroid, Tirosint or another levothyroxine product would not necessarily restrict Euthyrox or apply outside the relevant jurisdiction.
What is the FDA regulatory status of Euthyrox?
Euthyrox is an FDA-approved prescription levothyroxine product. The product is regulated as a conventional small-molecule drug, not as a biologic. Biosimilar competition is therefore not relevant.
The key regulatory issues are:
- Dose consistency.
- Bioequivalence.
- Product switching.
- Manufacturing changes.
- Stability and potency.
- Labeling for administration and contraindications.
- Monitoring of thyroid-stimulating hormone after treatment changes.
Because levothyroxine is a narrow-therapeutic-index medicine, physicians often emphasize consistent administration and follow-up testing. Regulatory approval does not prevent generic substitution where the competing product is rated therapeutically equivalent.
How does Euthyrox compare with Synthroid and Tirosint?
| Factor | Euthyrox | Synthroid | Tirosint |
|---|---|---|---|
| Core dosage form | Tablet | Tablet | Softgel |
| Market position | International mature brand | Strong U.S. branded incumbent | Premium differentiated formulation |
| Generic exposure | High | High | Lower direct substitution for softgel |
| Price position | Generally standard branded or reimbursed price | Branded premium in some channels | Premium |
| Main advantage | Global scale and brand continuity | U.S. physician and patient familiarity | Formulation differentiation |
| Growth profile | Mature and defensive | Mature and defensive | Greater specialty-formulation opportunity |
| Patent value | Limited for core tablet | Limited for core tablet | More relevant formulation and delivery rights |
Euthyrox’s strongest competitive advantage is geographic breadth. Tirosint has a stronger product-differentiation argument. Synthroid has a stronger U.S. brand-recognition position in some prescribing and patient segments.
What generic launch scenarios exist for Euthyrox?
The standard generic launch scenario is already established. Future erosion is likely to occur through:
- Additional low-cost tablet suppliers.
- Pharmacy-level substitution.
- Payer-mandated generic use.
- Tender price reductions outside the United States.
- Switching between generic manufacturers.
- Expansion of liquid and softgel alternatives in selected patients.
A major new generic entrant would likely reduce price and increase substitution rather than create a sudden market discontinuity. A clinically differentiated liquid or softgel product could take share from both Euthyrox and standard generics without relying on a traditional patent cliff.
What is the investment and licensing outlook for Euthyrox?
Euthyrox is more suitable for cash-flow, geographic expansion or portfolio optimization strategies than for high-growth licensing based on exclusivity. Licensing value may exist in:
- Regional commercialization rights.
- Hospital and government tenders.
- Local manufacturing.
- Supply agreements.
- Reformulated oral delivery systems.
- Combination products or adherence-oriented packaging.
The public record does not identify a major recent Euthyrox licensing transaction that changes its global competitive position. Local partnerships remain commercially plausible because levothyroxine markets are fragmented by reimbursement, tender rules, registration requirements and distribution systems.
Key Takeaways
- Euthyrox is a mature levothyroxine sodium brand owned and marketed by Merck KGaA.
- Its underlying demand is stable because hypothyroidism requires chronic treatment.
- Merck does not disclose Euthyrox revenue separately, preventing a verified product-level financial series.
- Revenue is likely defensive rather than growth-oriented because generic levothyroxine is widely available.
- Core active-ingredient exclusivity has expired.
- The principal competitive risks are generic substitution, price pressure and tender erosion.
- Formulation-based competitors such as Tirosint have greater differentiation than standard levothyroxine tablets.
- Euthyrox has no biosimilar risk because it is a small-molecule drug, not a biologic.
- Manufacturing quality, supply continuity and brand retention are more important than patent duration.
- Commercial upside is concentrated in geographic rights, supply scale and differentiated delivery formats.
FAQs
Is Euthyrox the same as generic levothyroxine?
Euthyrox contains levothyroxine sodium, the same active ingredient used in generic levothyroxine. Products can differ in excipients, tablet formulation, manufacturer and dose consistency. FDA therapeutic-equivalence ratings determine whether a generic can be substituted under applicable law.
Does Euthyrox have a patent in the United States?
The core levothyroxine ingredient is long off patent. The conventional Euthyrox tablet does not have a current foundational patent barrier that prevents generic competition. Any relevant patent would need to be evaluated by product, claim scope and jurisdiction.
Is Euthyrox more profitable than Synthroid?
Public filings do not provide comparable product-level profitability for Euthyrox and Synthroid. Profitability depends on net price, rebates, manufacturing cost, channel mix, geographic exposure and brand retention.
Can patients switch from Euthyrox to another levothyroxine product?
Switching is possible, but thyroid-stimulating hormone monitoring may be appropriate after a product or dose change, particularly in patients with narrow therapeutic requirements. Product switching should follow prescribing and local regulatory practice.
Does Euthyrox have a liquid or softgel version?
Euthyrox is principally associated with tablet formulations. Liquid and softgel levothyroxine products, including Tirosint-SOL and Tirosint, compete in differentiated formulation segments.
References
-
Merck KGaA. (2023). Annual report 2023. https://www.merckgroup.com/en/annualreport/2023.html
-
Merck KGaA. (2024). Annual report 2024. https://www.merckgroup.com/en/annualreport.html
-
U.S. Food and Drug Administration. (2014). Levothyroxine sodium products: Guidance for industry. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2023). Euthyrox (levothyroxine sodium) tablets: Prescribing information. https://www.accessdata.fda.gov/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files ⟂
More… ↓
